A disease-modifying era
Promente is preparing and conducting clinical research into new medicines for Alzheimer disease. These studies may involve people with dementia symptoms, people with mild cognitive impairment and, in selected protocols, people with family risk who may not yet have clinical symptoms.
Robert Kucharski, MD, PhD, explains that neurodegenerative medicine has entered a period of rapid progress. Modern diagnostics can identify disease processes earlier, which supports better assessment of possible study participation before brain damage becomes advanced.
What the studies may involve
The center prioritizes phase III studies and mechanisms that have already been partly verified. In this type of research, previous stages have provided information about safety, possible side effects and preliminary clinical activity.
Depending on the protocol, studies may include people with visible symptoms, people with mild cognitive impairment and people in whom pathological proteins are already present even before clear memory symptoms appear.
Diagnosis and monitoring
Pathological protein accumulation can be assessed through cerebrospinal fluid testing or positron emission tomography. Each method has advantages and limitations, and the diagnostic path is chosen with attention to expected benefit, accuracy and burden for the participant.
Neuropsychological testing is also important. It helps determine the participant baseline status and later evaluate whether cognitive functions are stable, improving or worsening during the study.
Possible duration
Depending on symptom severity and the specific protocol, treatment and observation can last from two to six years. The purpose of this type of research is to evaluate whether an investigational intervention can influence disease course or dementia risk in selected participants. Outcomes for an individual participant cannot be predicted or guaranteed.